Table 1.
Clinical characteristics in RA-ILD and RA.
| RA-ILD (n = 100) | RA (n = 100) | P | |
|---|---|---|---|
| Male/female | 43/57 | 25/75 | 0.011 |
| Age (year, mean ± SD) | 63.89 ± 8.99 | 53.26 ± 13.24 | 0.000 |
| Disease duration (year, mean ± SD) | 9.87 ± 10.23 | 9.05 ± 8.28 | 0.941 |
| RF (IU/ml, mean ± SD) | 391.05 ± 413.34 | 221.02 ± 321.53 | 0.000 |
| ACPA (IU/ml, mean ± SD) | 828.77 ± 584.23 | 471.57 ± 549.60 | 0.000 |
| ESR (mm/h, mean ± SD) | 67.84 ± 34.42 | 62.88 ± 38.53 | 0.236 |
| CRP (mg/L, mean ± SD) | 32.72 ± 36.74 | 33.36 ± 37.49 | 0.846 |
| IgG (g/L, mean ± SD) | 14.68 ± 6.14 | 14.18 ± 3.85 | 0.953 |
| IgA (g/L, mean ± SD) | 3.32 ± 1.31 | 3.08 ± 1.34 | 0.156 |
| IgM (g/L, mean ± SD) | 1.52 ± 0.89 | 1.43 ± 0.77 | 0.424 |
| Treatment (users/nonusers) | 87/13 | 91/9 | 0.499 |
| NSAIDs (users/nonusers) | 58/42 | 69/31 | 0.142 |
| GCs (users/nonusers) | 18/82 | 16/84 | 0.851 |
| DMARDs (users/nonusers) | 11/89 | 22/78 | 0.056 |
| GCs + DMARDs (users/nonusers) | 38/62 | 25/75 | 0.067 |
| Biological agents (users/nonusers) | 4/96 | 11/89 | 0.105 |
ESR: erythrocyte sedimentation rate, RF: rheumatoid factor, ACPA: antibodies to cyclic citrullinated peptides, CRP: C-reactive protein, NSAIDs: nonsteroidal anti-inflammatory drugs, GCs: glucocorticoids, and DMARDs: disease-modifying antirheumatic drugs.